Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage

Hong Kong Medical Journal

Volumn 14, Issue 6, 2008, Pages 495-498

  Loong, Herbert H ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Gastrointestinal stromal tumors; Protein tyrosine kinases

Indexed keywords

CORTICOSTEROID; IMATINIB; SUNITINIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; DUODENOJEJUNOSTOMY; DUODENUM RESECTION; DYSPNEA; EMERGENCY WARD; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HEPATIC ARTERY; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERACANTHOSIS; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LIVER ARTERIOGRAPHY; LUNG FUNCTION TEST; MALE; PHYSICAL EXAMINATION; SURGICAL TECHNIQUE; THORAX RADIOGRAPHY; TUMOR BLEEDING; TUMOR VOLUME; VESICULAR RASH; BLEEDING; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

ANTINEOPLASTIC AGENTS; GASTROINTESTINAL STROMAL TUMORS; HEMORRHAGE; HUMANS; INDOLES; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; PYRROLES;

EID: 60849135748     PISSN: 10242708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Rubin BP, Fletcher JA, Fletcher CD. Molecular insights into the histogenesis and pathogenesis of gastrointestinal stromal tumors. Int J Surg Pathol 2000;8:5-10.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80.
3. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9.
4. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7.
5. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.
6. Ohnishi K, Sakai F, Kudoh S, Ohno R. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162-4.
7. Parker JC, Ivey CL, Tucker A. Phosphotyrosine phosphatase and tyrosine kinase inhibition modulate airway pressure-induced lung injury. J Appl Physiol 1998;85:1753-61.
8. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
9. Sunitinib Malate (Sutent) Monograph - Pfizer Oncology. Pfizer website: http://www.pfizer.ca. Accessed 5 Aug 2008.
10. John SK, Basu S, Lawrance RJ, Davies N. An unusual presentation of a gastrointestinal stromal tumour (GIST). World J Surg Oncol 2007;5:78.
11. Loughrey MB, Mitchell C, Mann GB, Michael M, Waring PM. Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol 2005;58:779-81.
12. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-8.
13. Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006;107:2833-41.